REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19

J Infect. 2020 Sep;81(3):e37-e38. doi: 10.1016/j.jinf.2020.06.063. Epub 2020 Jun 29.

Authors

Stefano Piaserico¹, Alberto Meneguzzo², Francesco Messina²

Affiliations

¹ Dermatology Unit, Department of Medicine, University of Padua, via Gallucci 4, Padua, Italy. Electronic address: stefano.piaserico@unipd.it.
² Dermatology Unit, Department of Medicine, University of Padua, via Gallucci 4, Padua, Italy.

No abstract available

Keywords: Biologic drugs; COVID-19; IL-17; Pulmonary fibrosis; SARS-CoV-2.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus*
COVID-19
Coronavirus Infections*
Humans
Interleukin-17
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Interleukin-17